Johnson & Johnson (NYSE ... schizophrenia and depression related to bipolar I or II disorder. It may also soon obtain approval for major depressive disorder. The blockbuster drug could generate ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

On January 22, Johnson & Johnson released financial ... the FDA approved Spravato for the treatment of MDD [major depressive disorder], which affects about 21 million Americans, according to ...

CAPLYTA net product sales grew to $199.2 million, representing a 51%increase over the same period in 2023Full year 2024 ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total ...

In a remarkable display of market confidence, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) stock has reached an all-time high, touching a price level of $128.01. According to InvestingPro data, the ...

The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...

In a recent special meeting, Firefly Neuroscience, Inc. (NASDAQ:AIFF), a Delaware-based prepackaged software company with a market capitalization of $122.84 million, received stockholder approval for ...